Catalyzing breakthroughs
Cambrian Bio is a clinical-stage drug development company developing therapeutics that will redefine healthcare in the 21st century.
Restoring metabolic function
Cambrian develops precision therapeutics targeting the critical metabolic pathways that decline with age including AMPK and mTOR.
Building medicines of the future
ATX-304, our lead asset, is the first AMPK Network Activator to enter clinical development, with positive Phase 1b data in obesity and prediabetes.
